NeuroPhage Pharmaceuticals Obtains $9,000,000 Series B Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3f9b4d97-9e7b-4607-9d71-a58eccc9a0c2&Preview=1
Date
3/9/2012
Company Name
NeuroPhage Pharmaceuticals
Mailing Address
222 3rd St. Cambridge, MA 02142
Company Description
NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
Website
http://www.neurophage.com
Transaction Type
Venture Equity
Transaction Amount
$9,000,000
Transaction Round
Series B
Proceeds Purposes
The company will use the financing to further the clinical development of NPT002.
M&A Terms
Venture Investor
Shire Pharmaceuticals
Venture Investor
Undisclosed